Vaccines, Combined

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

3 days ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application

2 months ago talkbio0Tagged Biologics License Application, Clinical Trials, COVID19 (disease), Effectiveness, Influenza, Moderna, mRNA-1083, Prices, United States Food and Drug Administration, Vaccines, Vaccines, Combined

Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price

Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial

1 year ago talkbio0Tagged COVID19 (disease), Immune response, Late-Stage Trial, Moderna, Respiratory viruses, SARS-CoV-2, Vaccines, Vaccines, Combined

Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses